Patents Assigned to HUMAB LLC
  • Patent number: 11117956
    Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: September 14, 2021
    Assignees: MedImmune, LLC, Humabs BioMed SA
    Inventors: Qun Wang, Charles Stover, Meghan Pennini, Chew-shun Chang, Xiaodong Xiao, Jamese Hilliard, Gilad Kaplan, Davide Corti, Elisabetta Cameroni, Martina Beltramello
  • Patent number: 8871207
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: Humabs, LLC
    Inventor: Antonio Lanzavecchia
  • Publication number: 20120076801
    Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
    Type: Application
    Filed: April 15, 2011
    Publication date: March 29, 2012
    Applicant: Humabs, LLC
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Publication number: 20120076802
    Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.
    Type: Application
    Filed: April 22, 2011
    Publication date: March 29, 2012
    Applicant: Humabs, LLC
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 8071371
    Abstract: A method for producing a clone of an immortalized human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalized human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalized human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: December 6, 2011
    Assignee: Humabs LLC
    Inventor: Antonio Lanzavecchia
  • Patent number: 7955599
    Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: June 7, 2011
    Assignee: Humabs, LLC
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 7947274
    Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: May 24, 2011
    Assignee: Humabs, LLC.
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Publication number: 20090081230
    Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
    Type: Application
    Filed: July 16, 2008
    Publication date: March 26, 2009
    Applicant: HUMAB LLC
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Publication number: 20080213265
    Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.
    Type: Application
    Filed: January 3, 2008
    Publication date: September 4, 2008
    Applicant: HUMAB LLC
    Inventors: Antonio Lanzavecchia, Annalisa Macagno